What is the diagnosis and appropriate treatment for a 33-year-old alcoholic male who wants to stop drinking and presents with anemia, severe thrombocytopenia, hyperbilirubinemia, low albumin, an AST/ALT ratio greater than 2, and a cholestatic pattern of liver enzymes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Diagnosis: Severe Alcoholic Hepatitis with Underlying Cirrhosis

This patient has severe alcoholic hepatitis (AH) with probable underlying cirrhosis, requiring immediate alcohol cessation, aggressive nutritional support, and consideration for corticosteroid therapy based on severity scoring.

Clinical Assessment

Your patient presents with classic features of alcoholic liver disease 1:

  • AST/ALT ratio of 3.3 (72/21.7) - strongly suggestive of alcoholic hepatitis (ratio typically >1.5-2.0 in AH)
  • Severe thrombocytopenia (40,000/µL) - indicates portal hypertension and likely underlying cirrhosis
  • Hyperbilirubinemia (12.54 mg/dL total) with mixed pattern (direct 6.09, indirect 6.45)
  • Hypoalbuminemia (2.33 g/dL) - reflects synthetic dysfunction
  • Anemia (Hb 10.3) and elevated monocytes (1850) - common in AH
  • Cholestatic pattern (elevated alkaline phosphatase 300, though GGT relatively low at 30.7)

The combination of anemia, thrombocytopenia, and hypoalbuminemia with portal hypertension features suggests this is alcoholic hepatitis superimposed on cirrhosis 1.

Severity Stratification (Critical Step)

Calculate the Modified Maddrey Discriminant Function (mDF) score immediately 1, 2:

You need the prothrombin time (PT) to calculate mDF = 4.6 × (patient PT - control PT) + serum bilirubin (mg/dL)

Also calculate MELD score 1, 3:

  • MELD = 3.78×ln[bilirubin(mg/dL)] + 11.2×ln[INR] + 9.57×ln[creatinine(mg/dL)] + 6.43

With bilirubin 12.54 and creatinine 0.67, you need the INR to complete this calculation.

Severity Thresholds:

  • mDF ≥32 = severe AH with 28-day mortality 30-50% without treatment 1
  • MELD >20-21 = high 90-day mortality 1, 3
  • Glasgow score ≥9 = high 28-day mortality 1

Immediate Management Algorithm

Step 1: Exclude Contraindications to Specific Therapy 4, 2, 5

Screen for:

  • Active gastrointestinal bleeding
  • Active uncontrolled infection (check blood cultures, urinalysis, diagnostic paracentesis if ascites present)
  • Acute pancreatitis
  • Acute kidney injury/hepatorenal syndrome
  • Other causes: viral hepatitis (HBV, HCV), drug-induced liver injury, autoimmune hepatitis

Critical pitfall: Up to 20% of patients with suspected AH have alternative or additional diagnoses 1. However, given the classic AST/ALT ratio >2 and history, AH is most likely.

Step 2: Universal Interventions (All Patients) 4, 1, 4, 3

Alcohol Abstinence (Class I, Level B):

  • Complete and immediate cessation 4, 3
  • Assess for withdrawal risk - provide benzodiazepines if needed
  • Addiction medicine consultation during hospitalization

Aggressive Nutritional Support (Class I, Level B):

  • Target: 1.2-1.5 g/kg/day protein and 35-40 kcal/kg/day 1
  • If critically ill: 1.5 g/kg/day protein and 40 kcal/kg/day 1
  • Enteral nutrition preferred (oral supplements or nasogastric if unable to take orally) 4
  • Multiple small meals (6 meals/day including late evening snack) 1
  • Daily caloric intake <21.5 kcal/kg/day associated with 65.8% mortality vs 33.1% with adequate intake 3

Vitamin and Mineral Supplementation (Class B1):

  • Thiamine (vitamin B1) - critical to prevent Wernicke's encephalopathy
  • Folic acid
  • Vitamin B12
  • Pyridoxine (B6)
  • Vitamin A, D
  • Zinc supplementation (therapeutic doses) - improves gut barrier integrity 3
  • Multivitamin daily 1

Step 3: Specific Medical Therapy Based on Severity

If mDF ≥32 or MELD >20 (Severe Disease):

First-Line: Prednisolone 40 mg/day for 28 days (Class I, Level A) 1, 4, 6, 3, 5

  • Improves 28-day survival (84.6% vs 65.1% placebo, p=0.001) 1
  • Use prednisolone (not prednisone - better bioavailability in liver disease)
  • Alternative: Methylprednisolone 32 mg/day 6
  • Contraindications: active GI bleeding, uncontrolled infection, renal failure, pancreatitis 1, 4

Assess Response at Day 7 - Calculate Lille Score 6, 5:

  • Lille score ≥0.45 = non-responder → discontinue steroids 6
  • Lille score <0.45 = responder → continue full 28-day course

Consider Adding N-Acetylcysteine (NAC) 6:

  • NAC + corticosteroids showed 1-month and 3-month survival benefit in one trial
  • Dose: Standard NAC protocol
  • Weak recommendation (G2+) - not yet standard but reasonable to consider 6

If Contraindications to Steroids:

Pentoxifylline is NO LONGER RECOMMENDED 6:

  • Previously suggested at 400 mg TID for 4 weeks 4
  • Recent evidence shows ineffectiveness - French guidelines 2022 state "must no longer be offered" (G1-) 6
  • Focus on supportive care and nutritional therapy instead

If mDF <32 and MELD <20 (Mild-Moderate Disease):

Supportive Care Only (Class III, Level A) 4:

  • Nutritional support and abstinence
  • Close monitoring
  • No benefit from corticosteroids or other specific medical interventions 4

Additional Critical Management Points

Monitor for Complications:

Acute Kidney Injury/Hepatorenal Syndrome:

  • Severe thrombocytopenia and SIRS increase AKI risk 3
  • Avoid nephrotoxins: NSAIDs, aminoglycosides, IV contrast 3
  • Cautious diuretic use
  • Early albumin + vasoconstrictors if HRS develops 3

Infection Surveillance:

  • 12-26% have infection at admission, up to 50% develop infection on steroids 3
  • If on steroids: extensive bacteriological workup for any fever or clinical deterioration 6
  • Consider diagnostic paracentesis if ascites present (rule out spontaneous bacterial peritonitis)

Severe Thrombocytopenia (40,000/µL):

  • Bleeding risk - avoid invasive procedures unless essential
  • If liver biopsy needed: transjugular route only (reduces bleeding risk) 1, 5
  • Platelet transfusion only for active bleeding or pre-procedure

Role of Liver Biopsy:

Consider biopsy (transjugular route) if: 1, 5

  • Diagnostic uncertainty (atypical features)
  • Need to confirm diagnosis before corticosteroid therapy in severe cases
  • Prognostic information needed

Not routinely required - diagnosis can be made clinically with typical presentation 1, 2, 5

Prognosis and Follow-up

Short-term (3 months):

  • Mortality primarily related to severity of hepatitis and liver function improvement 6
  • Alcohol resumption has minimal impact on 3-month mortality 6

Long-term (beyond 3 months):

  • Abstinence is the dominant factor for survival 6, 3
  • 5-year survival: 80% with abstinence vs 50% with relapse 6
  • Addiction treatment must be systematically offered after AH episode 6

Common Pitfall: The relatively low GGT (30.7) is unusual but can occur in severe AH with cholestasis 7. The elevated direct bilirubin (6.09) and alkaline phosphatase suggest a cholestatic component, which is associated with worse prognosis 1, 8. This does not change management but reinforces the need for aggressive treatment.

Related Questions

Patient recently stopped alcohol, labs show AST 139 U/L, ALT 345 U/L, alkaline phosphatase 168 U/L—what is the recommended treatment now?
Does an aspartate aminotransferase (AST) level that is roughly twice the alanine aminotransferase (ALT) level indicate alcoholic liver disease?
In a 20‑year‑old male chronic alcoholic presenting with icterus, elevated total bilirubin, elevated direct and indirect bilirubin, markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), normal total protein, albumin, hemoglobin, white blood cell count and platelet count, neutrophil percentage 45.8% and lymphocyte percentage 41.8%, what is the diagnosis and the appropriate treatment with dosages?
How should a patient with alcoholic hepatitis who develops fever, chills, vomiting and markedly elevated AST (aspartate aminotransferase) and ALT (alanine aminotransferase) be managed?
What is the appropriate management for an alcoholic patient with total bilirubin 15 mg/dL, direct bilirubin 6 mg/dL, indirect bilirubin 9 mg/dL, aspartate aminotransferase (AST) 54 U/L, and prothrombin time 59 seconds?
Can an enema be used to treat intussusception in a child?
Can an evacuation enema be administered to a patient with intussusception?
When should a patient with mild anemia (hemoglobin 11.2 g/dL, hematocrit 35.6 %, mean corpuscular hemoglobin concentration 32.5 g/dL) be referred to a hematologist?
A patient on gabapentin 400 mg, quetiapine (Seroquel) 50 mg, lithium carbonate 600 mg, clozapine (Clozaril) 200 mg, and valbenazine (Ingrezza) 60 mg has psychosis and constipation; what medication adjustments should be made?
In a 4‑month‑old infant who completed a 10‑day course of ampicillin and cefotaxime for presumed meningitis (lumbar puncture unsuccessful) and now shows mildly dilated subarachnoid spaces on MRI, with negative cultures, normal CRP and CBC, and clinical improvement, is this finding likely due to prior meningitis or a congenital cause?
What is the most appropriate management for a smoker with daytime drowsiness, loud snoring, poor nighttime sleep, a short neck (short distance between the cricothyroid cartilage and sternum) and crepitations suggestive of obstructive sleep apnea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.